Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $28.83

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $28.83.

KURA has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, November 6th. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a report on Monday, November 4th. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and dropped their target price for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, UBS Group initiated coverage on shares of Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price objective on the stock.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new position in shares of Kura Oncology during the 3rd quarter valued at approximately $25,000. ProShare Advisors LLC increased its holdings in Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after buying an additional 1,588 shares in the last quarter. Aaron Wealth Advisors LLC raised its position in shares of Kura Oncology by 2.4% in the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after acquiring an additional 1,673 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after acquiring an additional 2,167 shares in the last quarter.

Kura Oncology Trading Down 3.5 %

NASDAQ KURA opened at $15.92 on Friday. Kura Oncology has a 12-month low of $8.80 and a 12-month high of $24.17. The company has a fifty day simple moving average of $18.50 and a two-hundred day simple moving average of $19.92. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.24 billion, a P/E ratio of -6.75 and a beta of 0.86.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.